A phase I clinical trial in BCa patients, is currently testing a LXR agonist (RGX-104) as a single agent or combined with nivolumab to strengthen the anti-tumor activity and the response to anti-PD-1 therapy (Schneider et al., 2019). The gene discussed is PDCD1; the disease is neoplasm.